Assembly Biosciences(US:ASMB) Globenewswireยท2025-10-14 11:00Core Insights - Assembly Biosciences, Inc. is participating in two upcoming investor conferences to discuss its innovative therapeutics targeting serious viral diseases [1][2][3] Group 1: Upcoming Events - Anuj Gaggar, MD, PhD, the chief medical officer, will present a pre-recorded fireside chat at the H.C. Wainwright Liver Disease Virtual Conference on October 21, 2025, starting at 7 a.m. Eastern Time [2] - Jason Okazaki, CEO and president, along with Dr. Gaggar, will present during the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025, at 11 a.m. Eastern Time [3] - Webcast registration for both events is available on Assembly Biosciences' website, with replays accessible after each event [3] Group 2: Company Overview - Assembly Biosciences is focused on developing small-molecule therapeutics aimed at serious viral diseases, particularly targeting herpesvirus, hepatitis B virus (HBV), and hepatitis delta virus (HDV) infections [4] - The company is led by a team experienced in virologic drug development, emphasizing its commitment to improving patient outcomes [4]